KR20190091339A - Pi3k델타 억제제로서의 이미다조[1,5-a]피라진 유도체 - Google Patents

Pi3k델타 억제제로서의 이미다조[1,5-a]피라진 유도체 Download PDF

Info

Publication number
KR20190091339A
KR20190091339A KR1020197019710A KR20197019710A KR20190091339A KR 20190091339 A KR20190091339 A KR 20190091339A KR 1020197019710 A KR1020197019710 A KR 1020197019710A KR 20197019710 A KR20197019710 A KR 20197019710A KR 20190091339 A KR20190091339 A KR 20190091339A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
chloro
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197019710A
Other languages
English (en)
Korean (ko)
Inventor
징 리
하이보 자오
즈위 왕
Original Assignee
베이진 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이진 엘티디 filed Critical 베이진 엘티디
Publication of KR20190091339A publication Critical patent/KR20190091339A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020197019710A 2016-12-07 2017-12-07 Pi3k델타 억제제로서의 이미다조[1,5-a]피라진 유도체 Ceased KR20190091339A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016108897 2016-12-07
CNPCT/CN2016/108897 2016-12-07
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Publications (1)

Publication Number Publication Date
KR20190091339A true KR20190091339A (ko) 2019-08-05

Family

ID=62491736

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019710A Ceased KR20190091339A (ko) 2016-12-07 2017-12-07 Pi3k델타 억제제로서의 이미다조[1,5-a]피라진 유도체

Country Status (16)

Country Link
US (2) US11136323B2 (https=)
EP (1) EP3551630A4 (https=)
JP (2) JP7064495B2 (https=)
KR (1) KR20190091339A (https=)
CN (2) CN110267959B (https=)
AU (2) AU2017372377B2 (https=)
BR (1) BR112019011847A2 (https=)
CA (1) CA3045959A1 (https=)
EA (1) EA201991355A1 (https=)
IL (2) IL266986B (https=)
MX (1) MX394882B (https=)
NZ (1) NZ754944A (https=)
SG (1) SG10201912192RA (https=)
TW (2) TW202233190A (https=)
WO (1) WO2018103688A1 (https=)
ZA (1) ZA201903286B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108684A (ko) * 2020-02-26 2021-09-03 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233190A (zh) * 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
JP2023503230A (ja) * 2019-11-21 2023-01-27 ベイジーン リミテッド Ｐｉ３キナーゼデルタ阻害剤との組合せで抗ｏｘ４０抗体を用いる癌治療の方法
JP2024521763A (ja) * 2021-05-27 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー Ｐｉ３ｋデルタ阻害剤の塩、その結晶形態、調製方法、及び使用
KR20240060647A (ko) * 2021-09-14 2024-05-08 베이진 엘티디 Btk 저해제와 pi3 키나제 저해제의 조합물을 이용하는 암 치료 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872204B1 (ko) 2003-10-15 2008-12-09 오에스아이 파마슈티컬스, 인코포레이티드 이미다조피라진 티로신 키나제 억제제
SG175195A1 (en) 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
CA2825028A1 (en) * 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
EP2802586B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
SG11201509842SA (en) 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20210317140A1 (en) * 2013-10-18 2021-10-14 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
TW202233190A (zh) * 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108684A (ko) * 2020-02-26 2021-09-03 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도

Also Published As

Publication number Publication date
US20220098202A1 (en) 2022-03-31
TW202233190A (zh) 2022-09-01
EA201991355A1 (ru) 2019-11-29
US20190367523A1 (en) 2019-12-05
TWI762534B (zh) 2022-05-01
EP3551630A4 (en) 2020-07-15
EP3551630A1 (en) 2019-10-16
AU2022203737A1 (en) 2022-06-23
CN114805366A (zh) 2022-07-29
CN110267959B (zh) 2022-05-27
IL290419B2 (en) 2023-02-01
US11136323B2 (en) 2021-10-05
WO2018103688A1 (en) 2018-06-14
IL266986A (en) 2019-07-31
ZA201903286B (en) 2021-01-27
JP2022090051A (ja) 2022-06-16
CA3045959A1 (en) 2018-06-14
SG10201912192RA (en) 2020-02-27
BR112019011847A2 (pt) 2019-10-29
MX394882B (es) 2025-03-24
IL290419A (en) 2022-04-01
IL290419B (en) 2022-10-01
US11725012B2 (en) 2023-08-15
MX2019006612A (es) 2019-08-01
IL266986B (en) 2022-03-01
CN110267959A (zh) 2019-09-20
AU2017372377A1 (en) 2019-07-18
JP7064495B2 (ja) 2022-05-10
NZ754944A (en) 2023-02-24
AU2017372377B2 (en) 2022-03-03
JP2020500909A (ja) 2020-01-16
TW201833113A (zh) 2018-09-16

Similar Documents

Publication Publication Date Title
KR101921486B1 (ko) ＰＡＲＰ억제제인 4Ｈ-피라졸로[1,5-ａ]벤즈이미다졸 화합물의 아날로그
KR102376354B1 (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도
US11725012B2 (en) Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
CN112243439A (zh) 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途
KR20230026288A (ko) Sos1 억제제 및 이의 용도
AU2019382504B2 (en) Cyclic ureas
WO2015104662A1 (en) Indazole compounds as irak4 inhibitors
US10239873B2 (en) 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same
JP7128264B2 (ja) ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体
CN112313234B (zh) 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物
HK40008309B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
HK40008309A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
EA040746B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ
EA040339B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3Kδ
HK40036174A (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000